Let's talk about Elan (NYSE: ELN ) this week. And of course, when I say Elan, I'm pretty much boiling it down to its Tysabri drug. A lot of the Irish drug maker's future is banking on the success of its multiple sclerosis drug, but does that make Elan a one-trick pony?
Wide product lines and deep pipelines are a blessing, but that's not the only way to win the game. I saw Amgen (Nasdaq: AMGN ) blaze through the 1990s on the heels of just two blockbuster drugs in Neupogen and Epogen.
And maybe having a diversified drug portfolio is overrated. As big as Pfizer (NYSE: PFE ) is, it's still trading a third lower than where it was three years ago. Other Big Pharma names like Merck (NYSE: MRK ) and Bristol-Myers Squibb (NYSE: BMY ) are starting to bounce back, but they're still far off their all-time highs.
So where does that leave us when it comes to Elan? Well, we're not all in agreement. Anders Bylund is feeling bullish about the drug maker's chances, while Brian Lawler is donning his flame-retardant suit to tackle the bearish case.
Who will win? It's Elan's story, now.
- Read the bull argument.
- Read the bear argument.
- Read the bullish rebuttal.
- Read the bearish rebuttal.
- Sound off in Motley Fool CAPS.
- Vote for the winner.